Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Of Arsenic Trioxide In Patients With Adenocarcinoma Of The Pancreas Refractory To Gemcitabine

NCT00053222 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT00053222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00053222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Of Arsenic Trioxide In Patients With Adenocarcinoma Of The Pancreas Refractory To Gemcitabine
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2003
Completion date
July 31, 2007
Enrollment
13 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer